News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Triphase Accelerator Corporation Announces Preclinical Data On Proteasome Inhibitor Marizomib At 2014 American Society of Clinical Oncology Annual Meeting



5/30/2014 7:36:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Triphase Accelerator Corporation, a private drug development accelerator dedicated to advancing compelling, well-differentiated drugs through Phase II proof-of-concept, today announced preclinical study results demonstrating that the combination of marizomib, Triphase’s highly-differentiated proteasome inhibitor, and pomalidomide (Pomalyst®) was synergistic in killing multiple myeloma cells. The marizomib data will be presented on Monday, June 2, in a poster session at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting in Chicago.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES